Evidence map›Paper›PMID 33626337›Full record

ArticleAmerican journal of human genetics2021

Integrative analysis of liver-specific non-coding regulatory SNPs associated with the risk of coronary artery disease.

Ilakya Selvarajan, Anu Toropainen, Kristina M Garske, Maykel López Rodríguez, Arthur Ko, Zong Miao, Dorota Kaminska, Kadri Õunap, Tiit Örd, Aarthi Ravindran and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Regulatory Plasticity of the Human Genome.Molecular biology and evolution · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Ilakya SelvarajanA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Anu ToropainenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Kristina M GarskeDepartment of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Maykel López RodríguezA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Arthur KoDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Zong MiaoDepartment of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Dorota KaminskaInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio campus PO Box 1627, 70211 Kuopio, Finland.
Kadri ÕunapA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Tiit ÖrdA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Aarthi RavindranA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Oscar H LiuA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Pierre R MoreauA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Ashik Jawahar DeenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Ville MännistöDepartment of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Calvin PanDepartment of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Anna-Liisa LevonenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Aldons J LusisDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Sami HeikkinenSchool of Medicine, Institutes of Biomedicine and Clinical Medicine, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland.
Casey E RomanoskiDepartment of Cellular and Molecular Medicine, The College of Medicine, The University of Arizona, Tucson, AZ 85721, USA.
Jussi PihlajamäkiInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio campus PO Box 1627, 70211 Kuopio, Finland; Departments of Medicine, Endocrinology, and Clinical Nutrition, Kuopio University Hospital, Kuopio, Finland.
Päivi PajukantaDepartment of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Minna U KaikkonenA. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, PO Box 1627, 70211 Kuopio, Finland. Electronic address: minna.kaikkonen@uef.fi.
University of Eastern Finland · FIUniversity of California, Los Angeles · USUniversity of Arizona · US

Funding

Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVIS, RICHARD C · 1985 to 2019
$50.2M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI George S Watts · 1994 to 2026
$36.7M
Genomics of dyslipidemia in MexicansR01HL095056 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PAJUKANTA, PAIVI · 2009 to 2018
$5.9M
Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis · 2019 to 2026
$4.6M
Systems genetics approach to inflammatory mechanisms in atherosclerosisR01HL147883 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 2019 to 2022
$3.0M
Functional genetic variants for type 2 diabetesU01DK105561 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MOHLKE, KAREN L. · 2015 to 2019
$2.3M
Mechanisms of ERG in Endothelial ActivationR01HL147187 · NHLBI · UNIVERSITY OF ARIZONA · PI ROMANOSKI, CASEY E · 2019 to 2023
$1.9M
Integrating functional genomics in primary human adipocytes to investigate gene regulatory circuitry for obesogenic cardiovascular traitsF31HL142180 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARSKE, KRISTINA MARIE · 2018 to 2020
$110k
NHLBI NIH HHS F31 HL142180NHLBI NIH HHS P01 HL028481NHLBI NIH HHS R01 HL095056NHLBI NIH HHS R01 HL147187NHLBI NIH HHS R01 HL147883NIDDK NIH HHS R01 DK117850NIDDK NIH HHS U01 DK105561NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

Genetic factors underlying coronary artery disease (CAD) have been widely studied using genome-wide association studies (GWASs). However, the functional understanding of the CAD loci has been limited by the fact that a majority of GWAS variants are located within non-coding regions with no functional role. High cholesterol and dysregulation of the liver metabolism such as non-alcoholic fatty liver disease confer an increased risk of CAD. Here, we studied the function of non-coding single-nucleotide polymorphisms in CAD GWAS loci located within liver-specific enhancer elements by identifying their potential target genes using liver cis-eQTL analysis and promoter Capture Hi-C in HepG2 cells. Altogether, 734 target genes were identified of which 121 exhibited correlations to liver-related traits. To identify potentially causal regulatory SNPs, the allele-specific enhancer activity was analyzed by (1) sequence-based computational predictions, (2) quantification of allele-specific transcription factor binding, and (3) STARR-seq massively parallel reporter assay. Altogether, our analysis identified 1,277 unique SNPs that display allele-specific regulatory activity. Among these, susceptibility enhancers near important cholesterol homeostasis genes (APOB, APOC1, APOE, and LIPA) were identified, suggesting that altered gene regulatory activity could represent another way by which genetic variation regulates serum lipoprotein levels. Using CRISPR-based perturbation, we demonstrate how the deletion/activation of a single enhancer leads to changes in the expression of many target genes located in a shared chromatin interaction domain. Our integrative genomics approach represents a comprehensive effort in identifying putative causal regulatory regions and target genes that could predispose to clinical manifestation of CAD by affecting liver function.

Indexed as

Genetic Predisposition to DiseaseAllelesChromatinCoronary Artery DiseaseEnhancer Elements, GeneticFemaleGenome-Wide Association StudyGenomicsHumansLiverMaleMolecular Sequence AnnotationOrgan SpecificityPolymorphism, Single NucleotidePromoter Regions, GeneticProtein BindingChromatincholesterolcoronary artery diseaseCRISPRenhancerfunctional genomicsGWAShepatocyteliverSNPSTARR-seq

Identifiers

PMID33626337
PMCPMC8008493
OpenAlexW3130314681

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.